Cargando…

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy

BACKGROUND: Reports on the clinical meaningfulness of outcome measures in spinal muscular atrophy (SMA) are rare. In this two-part study, our aim was to explore patients’ and caregivers’ views on the clinical relevance of the Hammersmith Functional Motor Scale Expanded- (HFMSE). METHODS: First, we u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pera, Maria C., Coratti, Giorgia, Forcina, Nicola, Mazzone, Elena S., Scoto, Mariacristina, Montes, Jacqueline, Pasternak, Amy, Mayhew, Anna, Messina, Sonia, Sframeli, Maria, Main, Marion, Lofra, Robert Muni, Duong, Tina, Ramsey, Danielle, Dunaway, Sally, Salazar, Rachel, Fanelli, Lavinia, Civitello, Matthew, de Sanctis, Roberto, Antonaci, Laura, Lapenta, Leonardo, Lucibello, Simona, Pane, Marika, Day, John, Darras, Basil T., De Vivo, Darryl C., Muntoni, Francesco, Finkel, Richard, Mercuri, Eugenio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324197/ https://www.ncbi.nlm.nih.gov/pubmed/28231823 http://dx.doi.org/10.1186/s12883-017-0790-9

Ejemplares similares

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
por: Montes, Jacqueline, et al.
Publicado: (2018)

2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
por: Stimpson, Georgia, et al.
Publicado: (2023)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
por: Ramsey, Danielle, et al.
Publicado: (2017)

Different trajectories in upper limb and gross motor function in spinal muscular atrophy
por: Coratti, Giorgia, et al.
Publicado: (2021)

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Longitudinal natural history of type I spinal muscular atrophy: a critical review
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study
por: Trucco, Federica, et al.
Publicado: (2021)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
por: Coratti, Giorgia, et al.
Publicado: (2021)

Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?
por: Pera, Maria Carmela, et al.
Publicado: (2020)

Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module
por: Berti, Beatrice, et al.
Publicado: (2021)

Early Gross Motor Milestones in Duchenne Muscular Dystrophy
por: Norcia, Giulia, et al.
Publicado: (2021)

Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities
por: Rodriguez-Torres, Rafael S., et al.
Publicado: (2023)

Development of an International SMA Bulbar Assessment for Inter-professional Administration
por: Dunaway Young, Sally, et al.
Publicado: (2023)

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Real-World Data on Access to Standards of Care for People With Spinal Muscular Atrophy in the UK
por: Muni-Lofra, Robert, et al.
Publicado: (2022)

Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study
por: Pera, Maria Carmela, et al.
Publicado: (2023)

Respiratory function and therapeutic expectations in DMD: families experience and perspective
por: Brogna, Claudia, et al.
Publicado: (2020)

Prevalence of Pain within Limb Girdle Muscular Dystrophy R9 and Implications for Other Degenerative Diseases
por: Richardson, Mark, et al.
Publicado: (2021)

Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018)

Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement
por: Ramsey, Danielle, et al.
Publicado: (2022)

New therapies for spinal muscular atrophy: where we stand and what is next
por: Antonaci, Laura, et al.
Publicado: (2023)

Body mass index in type 2 spinal muscular atrophy: a longitudinal study
por: Ferrantini, Gloria, et al.
Publicado: (2022)

A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable?
por: Chieffo, Daniela P. R., et al.
Publicado: (2023)

Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
por: Catapano, Francesco, et al.
Publicado: (2016)

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients
por: Pane, Marika, et al.
Publicado: (2021)

Language Development in Preschool Duchenne Muscular Dystrophy Boys
por: Chieffo, Daniela Pia Rosaria, et al.
Publicado: (2022)

Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Screening of Neonatal UK Dried Blood Spots Using a Duplex SMN1 Screening Assay
por: Adams, Stuart P., et al.
Publicado: (2021)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
por: Servais, Laurent, et al.
Publicado: (2022)

Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy
por: Brogna, Claudia, et al.
Publicado: (2021)

Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
por: Weststrate, Harriet, et al.
Publicado: (2022)

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
por: Pane, Marika, et al.
Publicado: (2022)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Assessing floppy infants: a new module
por: Cutrona, Costanza, et al.
Publicado: (2022)

Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function †
por: Dunaway Young, Sally, et al.
Publicado: (2023)

Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy
por: Brogna, Claudia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hups7ihc87cbt08q2m9ng57j5t